You searched for "radiotherapy"

202 results found

EMUC19 - 11th European Multidisciplinary Congress on Urological Cancers

Don’t miss the great opportunity to present your innovative research or to attend the 11th European Multidisciplinary Congress on Urological Cancers (EMUC19) from 14-17 November 2019 in Vienna, Austria. Registration is now open. You can submit your onco-urology abstract before...

Prostate cancer

Case 1 What is prostate specific antigen (PSA) and what is its function? According to the ERSPC Trial (at 13 years), what was the number needed to screen and diagnosed to prevent one prostate cancer death and what was the...

Prostate cancer survivorship: a new path for uro-oncology

Over two million people in England have a diagnosis of cancer [1]. Of this figure, over 250,000 have been diagnosed with prostate cancer [2]. However, during the next decade, a rapid increase in the number of new cancer diagnoses, as...

Recent developments in bladder cancer

There have been some exciting developments in bladder cancer over the last few years. Immunotherapy has prolonged survival in a proportion of patients with metastatic disease, with sustained efficacy in some. Advances in genetic analysis and molecular subtyping make personalised...

Bladder cancer: where are we with intravesical therapies?

In the United Kingdom, almost 10,500 new cases of bladder cancer were identified in 2013, with over 5000 deaths in 2012 [1]. Seventy percent of new cases will be non-muscle invasive bladder cancer (NMIBC) at diagnosis and therefore will be...

Management of RHC in prostate cancer with selective embolisation and hyperbaric oxygen therapy

Prostate cancer is one of the most prevalent malignancies affecting men worldwide. Radiotherapy is a common treatment modality for localised and locally advanced prostate cancer. While radiotherapy can be effective, it may lead to complications such as radiation-induced haemorrhagic cystitis...

Radiation exposure – what is the optimal imaging modality in the follow-up of patients with urinary tract calculi?

Cumulative radiation dose is an important consideration in the nephrolithiasis patient population. Exposure to ionising radiation is known to be harmful and is associated with an increased risk of malignancy. Understanding radiation doses is necessary to make informed decisions regarding...

Update on immunotherapy for non-muscle invasive transitional cell carcinoma of the bladder

Patients with high-risk non-muscle invasive bladder cancer (NMIBC) that have failed Bacillus Calmette-Guérin (BCG) treatment are a difficult group to treat, and many may not be suitable for the preferred treatment option of radical cystectomy. Bladder-preserving treatments for BCG-unresponsive high-risk...

Prostate Cancer Focus

The ‘Prostate Cancer Focus 2021’ supplement from Urology News collates a range of articles covering the latest in the management of prostate cancer. The last year has seen plenty of innovation in the management of the condition, while the all-consuming...

Bladder cancer

Case 1 A 78-year-old female presents with a week history of painless haematuria. She’s a smoker and used to work in the textiles industry. She underwent a flexible cystoscopy. What does this image show? What are the two-week wait National...

25 Years of Prostate Cancer UK

As leading men’s health charity, Prostate Cancer UK, celebrates its 25th anniversary, top researchers reflect on the huge progress in testing, treatment and support for men over the past 25 years. 25 years of beating prostate cancer together Matthew Hobbs,...

Testing radical prostatectomy in men with prostate cancer and oligometastases to the bone: a randomised controlled feasibility study

Prostate cancer is the commonest cancer and the second most frequent cause of cancer death in Western men [1]. The recent STAMPEDE data suggests a median survival of just 42.1 months in the control arm of metastatic men [2]. Current...